ArticleHistopathology2019
Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
Article in Histopathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.Future oncology (London, England) · 2026Trial
- Tenosynovial giant cell tumor of the hip: a systematic review and institutional case series with Meta-analysis of recurrence and patient-reported outcomes.Journal of bone oncology · 2026Review
- Pexidartinib: Current advances in the symptomatic treatment of tenosynovial giant cell tumors.Cancer metastasis reviews · 2026Review
- TGCT of the shoulder - a case series and literature review.Archives of orthopaedic and trauma surgery · 2026Review
- Ultrasound-guided core needle joint biopsies in children: pathological findings, diagnostic performance, and clinical relevance.Pediatric radiology · 2026Article
- Single-Cell Analysis Clarifies Pathological Heterogeneity in Tenosynovial Giant Cell Tumor and Identifies Biomarkers for Predicting Disease Recurrence.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry.Future oncology (London, England) · 2025Observational
- Recurrent Diffuse Tenosynovial Giant Cell Tumor of the Temporomandibular Joint.Head and neck pathology · 2025Article
- Treatment Modalities for Refractory-Recurrent Tenosynovial Giant Cell Tumor (TGCT): An Update.Medicina (Kaunas, Lithuania) · 2024Review
- Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.Future oncology (London, England) · 2024Observational
- Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies.The oncologist · 2023Article
- A novel colony-stimulating factor 1 (CSF1) translocation involving human endogenous retroviral element in a tenosynovial giant cell tumor.Genes, chromosomes & cancer · 2023Article
- A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis.Journal of surgical oncology · 2022Observational
- Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue.Diagnostic pathology · 2022Article
- Surgical management of 144 diffuse-type TGCT patients in a single institution: A 20-year cohort study.Journal of surgical oncology · 2022Article
- Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2022Article
- Case Report: Giant Cell Tumor of Tendon Sheath After Breast Augmentation.Frontiers in oncology · 2022Article
- Tumor location and type affect local recurrence and joint damage in tenosynovial giant cell tumor: a multi-center study.Scientific reports · 2021Article
- PDGFB RNA in situ hybridization for the diagnosis of dermatofibrosarcoma protuberans.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.Orphanet journal of rare diseases · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
aimsLocalised- and diffuse-type tenosynovial giant cell tumours (TGCT) are regarded as different clinical and radiological TGCT types. However, genetically and histopathologically they seem indistinguishable. We aimed to correlate CSF1 expression and CSF1 rearrangement with the biological behaviour of different TGCT-types with clinical outcome (recurrence). METHODS AND
resultsAlong a continuum of extremes, therapy-naive knee TGCT patients with >3-year follow-up, mean age 43 (range = 6-71) years and 56% females were selected. Nine localised (two recurrences), 16 diffuse-type (nine recurrences) and four synovitis as control were included. Rearrangement of the CSF1 locus was evaluated with split-apart fluorescence in-situ hybridisation (FISH) probes. Regions were selected to score after identifying CSF1-expressing regions, using mRNA ISH with the help of digital correlative microscopy. CSF1 rearrangement was considered positive in samples containing >2 split signals/100 nuclei. Irrespective of TGCT-subtype, all cases showed CSF1 expression and in 76% CSF1 rearrangement was detected. Quantification of CSF1-expressing cells was not informative, due to the extensive intratumour heterogeneity. Of the four synovitis cases, two also showed CSF1 expression without CSF1 rearrangement. No correlation between CSF1 expression or rearrangement with clinical subtype and local recurrence was detected. Both localised and diffuse TGCT cases showed a scattered distribution in the tissue of CSF1-expressing cells.
conclusionIn diagnosing TGCT, CSF1 mRNA-ISH, in combination with CSF1 split-apart FISH using digital correlative microscopy, is an auxiliary diagnostic tool to identify rarely occurring neoplastic cells. This combined approach allowed us to detect CSF1 rearrangement in 76% of the TGCT cases. Neither CSF1 expression nor presence of CSF1 rearrangement could be associated with the difference in biological behaviour of TGCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.